CRC

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024
NSCLC, BTK, CRC, AACR, SMARCA2, BCL2, Breast, Breast cancer, Webcast, Science, CDK9, Chromatin, Pharmaceutical industry

WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place from April 5 to 10, 2024.

Key Points: 
  • WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place from April 5 to 10, 2024.
  • Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude, stated, “We look forward to sharing data on the preclinical characterization of our lead oral SMARCA2 degrader, PRT7732, which is on track to advance into Phase 1 clinical development in the second half of this year, and to presenting additional preclinical data for our highly selective and potent CDK9 inhibitor, PRT2527, that supports its potential therapeutic value in combination with BTK and BCL2 inhibitors in lymphoid malignancies.
  • To attend in person or via webcast, visit: https://edge.media-server.com/mmc/p/5dwkjbcy .
  • A replay of the webcast will be available on the Prelude website for 90 days.

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
BRAF, NSCLC, Therapy, CRC, AACR, CCCC

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the acceptance of two preclinical poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024 in San Diego, California.

Key Points: 
  • WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the acceptance of two preclinical poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024 in San Diego, California.
  • Details of the posters are as follows:
    Title: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis
    In November 2023, C4T made the strategic decision to discontinue clinical development of CFT8634 based on clinical data from the Phase 1 trial.

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Retrieved on: 
Tuesday, March 5, 2024
Senior, Biotechnology, NPV, PMA, Messenger, FDA, Partnership, Marketing, PPV, Food, CRC, AA, Biomarker, Science, Quest Diagnostics, THA, Patient, Clinical trial, Survival, DRS, Colorectal cancer, Gene expression, Medical imaging

In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.

Key Points: 
  • In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.
  • The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert® via partnerships with third-party laboratories.
  • “Detecting AA lesions allows for early intervention and significantly increases the chance of successful treatment and survival.
  • The study’s primary objectives include calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in average-risk subjects for CRC and AA.

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Retrieved on: 
Wednesday, February 28, 2024
Cetuximab, Research, Castration, PRS, Intellectual property, Patient, Pancreatic cancer, HNSCC, EAP, Eli Lilly and Company, CRPC, Drug design, BLA, FTD, HER2, MET, Congress, Afatinib, Partnership, NSCLC, CD3, EGFR, ESMO, BTD, Betta, CRC, AACR, Safety, Biomarker, RECIST, Clinical trial, Oncology, Prostate cancer, Neoplasm, FDA, Pembrolizumab, Lung, Disease, Travel, Pharmaceutical industry

Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.

Key Points: 
  • Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.
  • Merus plans to report initial interim efficacy and safety data from this cohort in the second quarter of 2024.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.
  • Merus also achieved an additional milestone of $1 million for candidate nomination in the fourth quarter of 2023.

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

Retrieved on: 
Wednesday, February 28, 2024
Neoplasm, RMB, SHPL, Net, EZH2, Growth, FC, Tax, Follicular lymphoma, FX, Fast Track, TCFD, Ethics, Marketing, RCC, Health, CER, Sintilimab, ITP, Disclosure, Plasma protein binding, Lancet, MET, Completeness, D-19, Paclitaxel, Met, NDA, NSCLC, EGFR, NRDL, Atopic dermatitis, ESG, CRC, PD-1, Completion, Phases of clinical research, Task force, Half-life, Chills, Potential, Breakthrough therapy, NMPA, Investment, FGFR, Research, PFS, AstraZeneca, EMA, ADS, Annual report, ASCO, FDA, Carbon accounting, VEGFR, Lung, COVID-19, Alopecia areata, PMDA, Lilly, Patient, Cancer, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:​HCM; HKEX:​13), the innovative, commercial-stage biopharmaceutical company, today reports its financial results for the year ended December 31, 2023 and provides updates on key clinical and commercial developments. HUTCHMED to host results call and webcasts today at 7:30 a.m. EST / 12:30 p.m. GMT / 8:30 p.m. HKT in English, and at 8:30 a.m. HKT in Chinese (Putonghua) on Thursday, February 29, 2024.

Key Points: 
  • HUTCHMED is committed to progressively embedding sustainability into all aspects of our operations and creating long-term value for our stakeholders.
  • The 2023 Sustainability Report will be published alongside our 2023 Annual Report in April 2024 and will include further information on HUTCHMED sustainability initiatives and their performance.
  • Net Income attributable to HUTCHMED for 2023 was $100.8 million compared to Net Loss attributable to HUTCHMED of $360.8 million in 2022.
  • The net income attributable to HUTCHMED in 2023 was $0.12 per ordinary share / $0.59 per ADS49, compared to net loss attributable to HUTCHMED of $0.43 per ordinary share / $2.13 per ADS in 2022.

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, February 28, 2024
Active, VSIG4, MSS, National Cancer Institute, Society, Sensei, Lung cancer, Patient, Immunotherapy, Trial of the century, Head, Neoplasm, VISTA, SITC, MBA, Annual general meeting, Therapy, Histology, Biology, NSCLC, ESMO, Kinetics, CRC, PD-1, Conference, Safety, Cemiplimab, Pharmacokinetics, CRADA, CD39, IND, Colorectal cancer, Translation, NCI, Aes, Part-time, FDA, Research and development, Administration, KOL, Cancer, Pharmaceutical industry

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2023, and provided corporate updates.

Key Points: 
  • “2023 saw the entry of our differentiated anti-VISTA antibody, SNS-101, into clinical development,” said John Celebi, President and Chief Executive Officer.
  • Recent updates include:
    A total of 33 patients have been treated with SNS-101 +/- Libtayo in the dose escalation phase of this study.
  • On October 23, 2023 , Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

CorVel Launches “Center of Excellence” for Vocational Evaluation Services

Retrieved on: 
Wednesday, February 28, 2024
Workplace, CorVel Corporation, Risk management, Case management, Person-centered therapy, CRC, CDMS, Employment, Research, Nursing

They can encompass specific claim needs such as ergonomic evaluations, vocational testing, onsite job analysis, or employment potential evaluations.

Key Points: 
  • They can encompass specific claim needs such as ergonomic evaluations, vocational testing, onsite job analysis, or employment potential evaluations.
  • In addition, they can provide specialty services for claims that are stalled or need direction or that may be denied or litigated.
  • Vocational evaluations are a cost-effective alternative to vocational rehabilitation case management and can provide claim specialists assessments and testing that lead to efficient return-to-work strategies.
  • “The pandemic has changed the nature of vocational evaluation services,” said Lea K. Gallop, a CorVel Case Management Manager.

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Retrieved on: 
Tuesday, February 27, 2024
Gynaecology, Culture, Blood, Urology, Gastroenterology, CRC, FIT, Internal medicine, The German, Practitioner, Congress, Colorectal cancer, DNA, Cancer, Pharmaceutical industry

This data underscores the significant impact gynecologists have in the early detection and prevention efforts against CRC.

Key Points: 
  • This data underscores the significant impact gynecologists have in the early detection and prevention efforts against CRC.
  • The Gynecology Congress is a premier event dedicated to gynecological health, offering Mainz Biomed an invaluable opportunity to connect with these vital healthcare providers.
  • This effort is aimed at increasing brand awareness and establishing ColoAlert® as a key component in medical practices for CRC screening.
  • In the coming months, Mainz Biomed will continue to actively participate in medical conferences that cater to its key demographic.

Carnegie Clean Energy to Present at Clean/Renewable Energy Virtual Investor Conference February 22nd

Retrieved on: 
Thursday, February 22, 2024
OTCQB, Aquaculture, NREL, Intelligence, National Renewable Energy Laboratory, Access, CRC, Conference, ASX, Electricity, LCOE, Hewlett Packard Enterprise, Technical support, Primary energy, Renewable energy

NORTH FREMANTLE, Australia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Carnegie Clean Energy (OTCQB: CWGYF, ASX: CCE), based in North Fremantle, Australia, focused on Ocean Energy, today announced that Jonathan Fievez, CEO, will present live at the Clean/Renewable Energy Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on February 22, 2024.

Key Points: 
  • NORTH FREMANTLE, Australia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Carnegie Clean Energy (OTCQB: CWGYF, ASX: CCE), based in North Fremantle, Australia, focused on Ocean Energy, today announced that Jonathan Fievez, CEO, will present live at the Clean/Renewable Energy Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on February 22, 2024.
  • Carnegie Clean Energy has secured support through the US Testing Expertise and Access to Marine Energy Research (TEAMER) program.
  • Carnegie Clean Energy (OTCQB: CWGYF, ASX: CCE) is a technology developer focused on delivering ocean energy technologies to make the world more sustainable.
  • Carnegie Technologies Spain and CETO Wave Energy Ireland is a wholly owned subsidiary of Carnegie Clean Energy.

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 22, 2024
BRAF, PD, Research, International Myeloma Foundation, Sale, Lung cancer, Workforce, Poster, Melanoma, P-value, Clinical trial, ATM, BCMA, Therapy, CCCC, Roche, Completeness, CRC, AACR, Conference, Colorectal cancer, Merck, NHL, Research and development, Cancer, Dexamethasone, Administration, Patient, Finance, Biogen, Pharmaceutical industry

WATERTOWN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended December 31, 2023, as well as recent business updates.

Key Points: 
  • As of February 2024, three escalation cohorts are complete and dose escalation continues with a fourth dose level currently enrolling.
  • In December 2023, C4T and Merck entered into a license and research collaboration to discover and develop degrader antibody conjugates.
  • Net loss per share for the year ended December 31, 2023 was $2.67, compared to $2.62 for the year ended December 31, 2022.
  • Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of December 31, 2023 were $281.7 million, compared to $337.1 million as of December 31, 2022.